A First-in-Class Nasal Airway Device
Redefining Airway Management for all healthcare settings
Fast, Safe, and Ready to Scale in a $4B+ Global Market
Redefining Airway Management for all healthcare settings
Fast, Safe, and Ready to Scale in a $4B+ Global Market
Positioned to capture significant share in a rapidly growing market
Current nasal intubation device market valuation
7.2% CAGR growth trajectory
Broader airway management market annually
| Healthcare Benefit | Estimated Savings |
|---|---|
| 1. Avoiding Paralytic Drugs | $100M — $300M/year |
| 2. Shorter ICU Stays (Less Ventilation) | $350M — $1B/year |
| 3. Avoiding Complications (Neuropathy, Vocal Cord) | $200M — $500M/year |
| 4. Avoiding Sedation-Related Complications (Delirium) | $200M — $2B/year |
| TOTAL ANNUAL SAVINGS | $850M — $3.8B/year |
| General Anesthesia (GA) | Price |
|---|---|
| Nasal | $1.80 |
| IV 20g | $2.20 |
| 500 mL NS 0.9% | $3.80 |
| IV tubing | $1.80 |
| IV tubing extension | $2.00 |
| Propofol 200mg vial x 2 | $2.80 |
| Zofran 4mg vial | $0.40 |
| Fentanyl 100mg vial | $0.85 |
| Ancef 1g vial | $1.10 |
| Rocuronium 50mg vial x 1 | $8.60 |
| Neostigmine 10mg vial x 1 | $4.85 |
| Glycopyrrolate 0.2 mg vial x 3 | $10.20 |
| Fentanyl 100mg vial x 2 | $1.70 |
| Sevoflurane vial x 1 | $105.50 |
| Dantrolene *required in the room, not to be used** | $924.30 |
| Nasal ET tube #7 | $7.30 |
| Ventilation circuit | $9.45 |
| McGills | (?) |
| Intubation blades | $185 |
| ETT extension accordion | (?) |
| Totals: | $1,276.50 |
Paralytic use: 40% of 40,000,000 → 16,000,000 cases using paralytics/year.
Clinically-significant complication rate: 0.5% of paralytic cases → 80,000 complications/year.
| Setting | Share | Complications | Annual Cost |
|---|---|---|---|
| Ambulatory | 30% | 24,000 | $1.488 billion/year |
| Oral / Maxillofacial | 5% | 4,000 | $248 million/year |
| Plastic / Cosmetic | 5% | 4,000 | $248 million/year |
| ENT | 10% | 8,000 | $496 million/year |
| DoD | 3% | 2,400 | $148.8 million/year |
| Other | 47% | 37,600 | $2.3312 billion/year |
| Total | ≈ $4.96 billion | ||
Co-Founder & CEO, Amnea Corp
Alexander Guizzotti is the visionary inventor behind AMtubation®, holding 3 U.S. Patents for this revolutionary nasal airway technology.
Working alongside Dr. Uday Reebye in surgical centers from 2019-2023, Alexander led the development through 3 years of rigorous surgical trials. From 2023-2025, Alexander transformed an innovative concept into a patient-safe, commercially-ready prototype to manufacture, changing the landscape of healthcare.
His dedication to solving critical challenges in airway management, resulted due to his mother being diagnosed with cancer. The relentless pursuit to ensure his mother would live, created the environment in oral surgery and anesthesia which lead to a first-in-class device promising to revolutionize emergency medicine, anesthesia, and surgical procedures worldwide.
World-Class Experts Driving Innovation in Airway Management
Anesthesiologist
Diplomate of the National Dental Board of Anesthesiology and Fellow of the American Society of Dental Anesthesiology. Assistant Professor at USC School of Dentistry.
Dentist to the Stars
Graduate of Case Western Reserve School of Dentistry and F.A.C.E. Institute. Renowned for world-class cosmetic and reconstructive dentistry with decades of expertise.
Pediatric Emergency Medicine
Completed emergency medicine fellowship at Cincinnati Children's Hospital. Associate Professor at Stollery Children's Hospital with extensive pediatric emergency expertise.
Backed by Leading Physicians and Key Opinion Leaders
MD, DMD
Oral & Maxillofacial Surgery
Chief Medical Advisor
MD, DMD
Oral & Maxillofacial Surgery
Medical Advisor
MD
Anesthesiology
Medical Advisor
MD
Internal Medicine
Medical Advisor
DMD
Dentistry
Medical Advisor
DMD
Dentistry
Medical Advisor
MD
Anesthesiologist
Medical Advisor
"Nasopharyngeal passage and supraglottic placement of a 5.0 oral endotracheal tube for management of difficult airways during office-based procedural sedation"
Dowsett, Khan, Souza, Reebye, et al. - National Publication
Patented Innovation Designed for Superior Clinical Outcomes
Placement achieved within seconds in clinical trials
Nasal route above the cords for minimal invasiveness
Full ventilation support with secure seal
Suction and drug delivery when IV access delayed
Designed for various provider skill levels
Robust IP estate with utility and design patents
ENT, Emergency, Military, Pediatrics, Veterinary
510(k) exempt status - rapid path to market
AMtubation® vs. Industry Standards
| Feature | Competitors | AMtubation® |
|---|---|---|
| Nasal Tube as Endotracheal | ✗ | ✓ |
| Curvilinear Inflated Balloon | ✗ | ✓ |
| Lumens Can Anesthetize Vocal Cords | ✗ | ✓ |
| Multi-Use Lumens (Tri-Lumen) | ✗ | ✓ |
| Height-Based Color Indicators | ✗ | ✓ |
| Patented Jet Angle on Tube | ✗ | ✓ |
| Rapid Deployment (<10 seconds) | ✗ | ✓ |
Amnea Corp is exclusively represented by Vikings M&A for acquisition discussions and strategic partnerships.
Open to full acquisition, majority sale, or structured partnership arrangements
For investor inquiries, acquisition discussions, or partnership opportunities,
contact Vikings M&A or reach out directly through our advisory team.